Leerink Partnrs Weighs in on Kura Oncology Q2 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for shares of Kura Oncology in a report released on Wednesday, February 5th. Leerink Partnrs analyst J. Chang anticipates that the company will earn $0.14 per share for the quarter. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. Leerink Partnrs also issued estimates for Kura Oncology’s Q3 2025 earnings at ($0.08) EPS and Q4 2025 earnings at ($0.06) EPS.

Several other research analysts have also recently issued reports on the company. Lifesci Capital raised Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. Jefferies Financial Group decreased their target price on Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research note on Thursday, November 21st. BTIG Research cut Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday. Bank of America decreased their target price on Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, November 22nd. Finally, Stifel Nicolaus lowered Kura Oncology from a “buy” rating to a “hold” rating and decreased their price target for the company from $26.00 to $19.00 in a research report on Monday, October 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Kura Oncology has a consensus rating of “Moderate Buy” and an average target price of $27.13.

Kura Oncology Price Performance

Shares of NASDAQ KURA opened at $8.82 on Friday. Kura Oncology has a 1-year low of $6.98 and a 1-year high of $24.17. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The business’s fifty day moving average price is $8.79 and its two-hundred day moving average price is $15.11.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.01. During the same period last year, the business earned ($0.50) EPS.

Hedge Funds Weigh In On Kura Oncology

Large investors have recently made changes to their positions in the business. Moody Aldrich Partners LLC lifted its position in shares of Kura Oncology by 42.3% during the 4th quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company’s stock worth $1,251,000 after purchasing an additional 42,712 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Kura Oncology in the 4th quarter valued at approximately $436,000. Harbor Capital Advisors Inc. grew its stake in shares of Kura Oncology by 4.4% in the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock valued at $430,000 after purchasing an additional 2,076 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Kura Oncology by 0.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock valued at $7,997,000 after purchasing an additional 3,092 shares during the period. Finally, AQR Capital Management LLC grew its stake in shares of Kura Oncology by 251.5% in the 2nd quarter. AQR Capital Management LLC now owns 81,655 shares of the company’s stock valued at $1,681,000 after purchasing an additional 58,422 shares during the period.

Insiders Place Their Bets

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the sale, the insider now directly owns 88,253 shares of the company’s stock, valued at $694,551.11. This represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 12,255 shares of company stock valued at $100,739 over the last quarter. Insiders own 5.50% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.